ArticleBMC neurology2007
Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease.
Article in BMC neurology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Therapeutic targeting of fibrin-microglia interactions ameliorates Alzheimer's disease-related hyperexcitability and brain network dysfunction.bioRxiv : the preprint server for biology · 2026Article
- Proteome-Based Biomarkers for Alzheimer's Disease: Old Acquisitions and Innovative Proposals.International journal of molecular sciences · 2025Review
- Fibrinogen-tau Aggregates Exacerbate Tau Pathology and Memory Deficits in Alzheimer's Disease Model Mice.Neuroscience bulletin · 2025Article
- Association of preoperative to postoperative change in cerebrospinal fluid fibrinogen with postoperative delirium.BJA open · 2024Article
- Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer's disease? An umbrella review.IBRO neuroscience reports · 2024Review
- Fibrin-Targeting Immunotherapy for Dementia.The journal of prevention of Alzheimer's disease · 2023Article
- Review
- Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.Pharmacology & therapeutics · 2022Review
- Construction of Unified Human Antimicrobial and Immunomodulatory Peptide Database and Examination of Antimicrobial and Immunomodulatory Peptides in Alzheimer's Disease Using Network Analysis of Proteomics Datasets.Frontiers in genetics · 2021Article
- Epitope Mapping Immunoassay Analysis of the Interaction between β-Amyloid and Fibrinogen.International journal of molecular sciences · 2019Article
- Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics.Nature reviews. Neuroscience · 2018Review
- Blood will out: vascular contributions to Alzheimer's disease.The Journal of clinical investigation · 2018Review
- Soluble Fibrinogen Triggers Non-cell Autonomous ER Stress-Mediated Microglial-Induced Neurotoxicity.Frontiers in cellular neuroscience · 2018Article
- Variations in the cerebrospinal fluid proteome following traumatic brain injury and subarachnoid hemorrhage.Pathophysiology : the official journal of the International Society for Pathophysiology · 2017Article
- Article
- Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome.Electrophoresis · 2014Article
- A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid.Proteomics · 2013Article
- Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?The EPMA journal · 2013Article
- Novel adaptors of amyloid precursor protein intracellular domain and their functional implications.Genomics, proteomics & bioinformatics · 2012Article
- Fibrinogen and altered hemostasis in Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebrospinal fluid (CSF) may be valuable for exploring protein markers for the diagnosis of Alzheimer's disease (AD). The prospect of early detection and treatment, to slow progression, holds hope for aging populations with increased average lifespan. The aim of the present study was to investigate candidate CSF biological markers in patients with mild cognitive impairment (MCI) and AD and compare them with age-matched normal control subjects.
methodsWe applied proteomics approaches to analyze CSF samples derived from 27 patients with AD, 3 subjects with MCI and 30 controls. The AD group was subdivided into three groups by clinical severity according to clinical dementia rating (CDR), a well known clinical scale for dementia.
resultsWe demonstrated an elevated level of fibrinogen gamma-A chain precursor protein in CSF from patients with mild cognitive impairment and AD compared to the age-matched normal subjects. Moreover, its expression was more prominent in the AD group than in the MCI and correlated with disease severity and progression. In contrast, fibrinogen gamma-A chain precursor protein was detected very low in the age-matched normal group.
conclusionThese findings suggest that the CSF level of fibrinogen gamma-A chain precursor may be a candidate biomarker for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.